Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to -$134130.0.

  • Inhibikase Therapeutics' Cash from Financing Activities fell 17371.64% to -$134130.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $99.6 million, marking a year-over-year increase of 262446.62%. This contributed to the annual value of $103.5 million for FY2024, which is 113114.37% up from last year.
  • According to the latest figures from Q3 2025, Inhibikase Therapeutics' Cash from Financing Activities is -$134130.0, which was down 17371.64% from $31771.0 recorded in Q2 2025.
  • Inhibikase Therapeutics' 5-year Cash from Financing Activities high stood at $99.7 million for Q4 2024, and its period low was -$409662.0 during Q1 2021.
  • For the 5-year period, Inhibikase Therapeutics' Cash from Financing Activities averaged around $10.9 million, with its median value being $30831.5 (2021).
  • The largest annual percentage gain for Inhibikase Therapeutics' Cash from Financing Activities in the last 5 years was 169289351.02% (2021), contrasted with its biggest fall of 26378.62% (2021).
  • Quarter analysis of 5 years shows Inhibikase Therapeutics' Cash from Financing Activities stood at $29892.0 in 2021, then plummeted by 785.03% to -$204769.0 in 2022, then soared by 32.56% to -$138104.0 in 2023, then soared by 72280.72% to $99.7 million in 2024, then crashed by 100.13% to -$134130.0 in 2025.
  • Its Cash from Financing Activities was -$134130.0 in Q3 2025, compared to $31771.0 in Q2 2025 and $99.7 million in Q4 2024.